Protein-bound 3,4-dihydroxy-phenylanine (DOPA), a redox-active product of protein oxidation, as a trigger for antioxidant defences

Protein hydroperoxides and protein-bound 3,4-dihydroxy-phenylanine are amongst the major long-lived redox-active products during free radical attack on proteins. Protein-bound 3,4-dihydroxy-phenylanine can redox cycle between catechol and quinone form, and bind transition metals, whereas hydroperoxi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The international journal of biochemistry & cell biology 2007, Vol.39 (5), p.879-889
Hauptverfasser: Nelson, Michelle, Foxwell, A. Ruth, Tyrer, Peter, Dean, Roger T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Protein hydroperoxides and protein-bound 3,4-dihydroxy-phenylanine are amongst the major long-lived redox-active products during free radical attack on proteins. Protein-bound 3,4-dihydroxy-phenylanine can redox cycle between catechol and quinone form, and bind transition metals, whereas hydroperoxides are converted to stable hydroxides. The free amino acid 3,4-dihydroxy-phenylanine is a normal metabolite, an oxidation product of tyrosine, involved in pathways of dopamine and melanin production, and we have shown that it may be incorporated into protein-by-protein synthesis. However, physiological levels of protein-bound 3,4-dihydroxy-phenylanine are very low; yet remarkably elevated levels occur in some pathologies. We propose that, unlike free 3,4-dihydroxy-phenylanine, protein-bound 3,4-dihydroxy-phenylanine is a signal for the activation of cellular defences both against the oxidative fluxes during oxidative stress and against the oxidative damage which sometimes ensues. Unlike free 3,4-dihydroxy-phenylanine, the levels of protein-bound 3,4-dihydroxy-phenylanine can change 5–10-fold during oxidative damage in vivo, an appropriate property for a signalling molecule. We suggest mechanisms by which protein-bound 3,4-dihydroxy-phenylanine might trigger oxidative defences, via NF-κB and other transcription factors. Little evidence yet bears directly on this, but we discuss some implications of observations on free 3,4-dihydroxy-phenylanine supply to cells in vitro, to Parkinson's patients, and to animal models of the disease. Several of the effects of 3,4-dihydroxy-phenylanine in these situations may be mediated by the production and actions of protein-bound 3,4-dihydroxy-phenylanine. Some experimental tests of the hypothesis are outlined and some possible therapeutic implications.
ISSN:1357-2725
1878-5875
DOI:10.1016/j.biocel.2006.10.004